178 related articles for article (PubMed ID: 35536413)
1. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
[TBL] [Abstract][Full Text] [Related]
3. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
[TBL] [Abstract][Full Text] [Related]
4. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
[TBL] [Abstract][Full Text] [Related]
5. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Peichl P; Alten R; Galeazzi M; Lorenz HM; Nüßlein H; Navarro F; Elbez Y; Chartier M; Hackl R; Rauch C; Connolly SE
Wien Med Wochenschr; 2020 Apr; 170(5-6):132-140. PubMed ID: 31654156
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
[TBL] [Abstract][Full Text] [Related]
7. Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
Misaki K; Tamura N; Azuma T; Shinoda K; Tanaka M; Fujiwara H; Tsuboi H; Kasama T; Yoshimi R; Hanyu T; Kusaka Y; Hirao M; Onishi M; Uchino A; Izumiyama T; Yang KS; Ogawa N; Matsui K; Kurasawa K; Kawaai S; Yasuoka H; Okumura N; Ueda Y; Tanaka E; Inoue E; Tsuritani K; Matsumoto S; Yamanaka H; Harigai M
Mod Rheumatol; 2024 Feb; 34(2):297-306. PubMed ID: 37233722
[TBL] [Abstract][Full Text] [Related]
8. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
[TBL] [Abstract][Full Text] [Related]
9. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
Alten R; Mariette X; Lorenz HM; Galeazzi M; Cantagrel A; Nüßlein HG; Chartier M; Elbez Y; Rauch C; Le Bars M
RMD Open; 2017; 3(2):e000538. PubMed ID: 29435360
[TBL] [Abstract][Full Text] [Related]
10. Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study.
Flipo RM; Constantin A; Goupille P; Chartier M; Ohayon A; Mariette X
Clin Exp Rheumatol; 2024 Mar; ():. PubMed ID: 38436358
[TBL] [Abstract][Full Text] [Related]
11. The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.
Emery P; Tanaka Y; Bykerk VP; Bingham CO; Huizinga TWJ; Citera G; Huang KG; Wu C; Connolly SE; Elbez Y; Wong R; Lozenski K; Fleischmann R
Arthritis Res Ther; 2023 Apr; 25(1):67. PubMed ID: 37087459
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study.
Tanaka Y; Kubo S; Yamanaka H; Amano K; Hirata S; Tanaka E; Nagasawa H; Yasuoka H; Takeuchi T
Mod Rheumatol; 2014 Sep; 24(5):754-62. PubMed ID: 25036232
[TBL] [Abstract][Full Text] [Related]
13. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
Foo J; Morel C; Bergman M; Baerwald C; Rodriguez-Heredia JM; Marshall A; Polanco-Sánchez C; Postema R
Rheumatol Int; 2019 Sep; 39(9):1621-1630. PubMed ID: 31240388
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).
Tamura N; Azuma T; Misaki K; Yamaguchi R; Hirano F; Sugiyama E; Kanai D; Murakawa Y; Oribe M; Kimata T; Aoki K; Sugiura T; Takasugi K; Takakubo Y; Tomita Y; Isozaki T; Nanki T; Katsuyama N; Kuroiwa T; Oshikawa H; Kaneko M; Fujinaga H; Saito K; Tanaka E; Inoue E; Yoshizawa Y; Matsumoto S; Yamanaka H; Harigai M
Mod Rheumatol; 2022 Aug; 32(5):846-856. PubMed ID: 34915575
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Peichl P; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
Clin Exp Rheumatol; 2016; 34(3):489-99. PubMed ID: 26966919
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
[TBL] [Abstract][Full Text] [Related]
17. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
18. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
Westhovens R; Connolly SE; Margaux J; Vanden Berghe M; Maertens M; Van den Berghe M; Elbez Y; Chartier M; Baeke F; Robert S; Malaise M
Rheumatol Int; 2020 Sep; 40(9):1409-1421. PubMed ID: 32556473
[TBL] [Abstract][Full Text] [Related]
19. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.
Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N
Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039
[TBL] [Abstract][Full Text] [Related]
20. Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study.
Azuma T; Misaki K; Kusaoi M; Suzuki Y; Higa S; Kumon Y; Yoshitama T; Naniwa T; Yamada S; Okano T; Takeuchi K; Ikeda K; Higami K; Inoo M; Sawada T; Kang C; Hayashi M; Nagaya Y; Hagiwara T; Shono E; Himeno S; Tanaka E; Inoue E; Yoshizawa Y; Kadode M; Yamanaka H; Harigai M
Mod Rheumatol; 2023 Mar; 33(2):271-278. PubMed ID: 35389481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
